Inflammatory processes are accompanied by the posttranslational modification of certain arginine residues within proteins to yield citrulline, although it is largely unknown how this modification influences antigen presentation. We employed crystallographic and functional studies to investigate whether the exchange of arginine to citrulline affects the display of a peptide by two human major histocompatibility antigen class I subtypes, HLA-B*2705 and HLA-B*2709. Both differ only in residue 116 within the peptide binding groove despite their differential association with ankylosing spondylitis, an inflammatory rheumatic disorder. The crystal structures described here show that a modified self-peptide, pVIPR-U5 (RRKWURWHL; U ‫؍‬ citrulline), is presented by the two HLA-B27 molecules in distinct conformations. These binding modes differ not only drastically from each other but also from the conformations exhibited by the non-citrullinated peptide in a given subtype. The differential reactivity of HLA-B27-restricted cytotoxic T cells with modified or unmodified pVIPR supports the structural findings and shows that the presentation of citrullinated peptides has the potential to influence immune responses.
The citrullination of proteins is a posttranslational modification that influences immune responses and inflammatory reactions (1, 2) . It is catalyzed by peptidylarginine deiminases and involves the replacement of the terminal imino group within the side chain of an arginine residue of an extra-or intracellularly expressed protein by an amide group (3), i.e. a change from -(CH 2 ) 3 -NH-C(NH 2 )ANH 2 ϩ to -(CH 2 ) 3 -NH-C(NH 2 )AO. The length of the residue side chain and its hydrogen bonding potential are, thus, retained but not its positive charge. Although exceptions have been found (for review, see Ref. 3) , citrullinated proteins must usually be regarded as neoantigens as they do not participate in the thymic selection of T cells. Consequently, it has recently been demonstrated that major histocompatibility complex (MHC) 3 class II-restricted T cells are able to distinguish between citrullinated and the respective unmodified peptides presented by MHC antigens (1, 4) .
In autoimmune disorders, in which inflammatory lesions are common, citrullination of proteins is apparently a general phenomenon, irrespective of the association of different MHC genes with a given disease (2, 5, 6) . Because this protein modification has also consistently been found within synovial tissue from patients with reactive arthritis, an HLA-B27-associated disorder (5), fragments derived from citrullinated polypeptides are most likely available for presentation by MHC antigens in patients with ankylosing spondylitis (AS) as well. This is a chronic inflammatory spondyloarthropathy that is even stronger associated with HLA-B27 than reactive arthritis (7) (8) (9) (10) . Studies in rats transgenic for HLA-B27 suggest a direct involvement of the HLA-B27 protein in the pathogenesis of AS (11) . Remarkably, the association with AS is HLA-B27 allele ("subtype")-dependent; for example, the ubiquitous, frequent HLA-B*2705 subtype (B*2705 in short) is AS-associated, whereas HLA-B*2709 (B*2709 in short) is not (9, 10, 12) . Both molecules are heterotrimeric cell surface glycoproteins consisting of a heavy chain (HC), ␤ 2 -microglobulin (␤ 2 m), and a peptide that is presented to effector cells (13, 14) . The B*2705 protein differs in only a single HC amino acid (Asp-116) from B*2709 (His-116) (12) . This residue is located at the floor of the peptide binding groove, contributes to shaping the F pocket, and participates in anchoring the peptide C-terminal side chain. The vast majority of the peptides constituting the B*2705 repertoire can also be found in B*2709 (15, 16) and are presumably displayed similarly, as indicated by comparative crystallographic analyses (17, 18) . Some peptides, however, are presented in drastically different conformations by B*2705 and B*2709 (14, 19 -21) . Particularly striking is the case of a self-peptide (pVIPR, RRKWRRWHL), which is derived from vasoactive intestinal peptide type 1 receptor (residues 400 -408). It is bound in a canonical conformation (13) , with the middle of the peptide bulging out of the B*2709 subtype binding groove, whereas B*2705 displays pVIPR in a dual binding mode (19) . One of the conformations observed in B*2705⅐pVIPR is identical to that seen in B*2709, whereas a salt bridge between the arginine residue at peptide position 5 (pArg5) and the polymorphic HC residue Asp-116 leads to different HC-peptide contacts in the other conformation. Both conformations are present in approximately equal amounts in the B*2705 peptide binding groove (19) .
We employed the subtypes B*2705 and B*2709 and a citrullinated version of pVIPR (pVIPR-U5; RRKWURWHL, U ϭ citrulline) to investigate whether the introduction of a citrulline (pCir5) into a peptide can lead to changes of its binding mode and whether these changes occur in an HLA-B27 subtype-specific manner. The two crystal structures described here show that the pVIPR-U5 binding mode in a given subtype is diametrically opposed to those exhibited by the unmodified pVIPR peptide. Furthermore, the modified peptide is presented in drastically deviating conformations by the two subtypes. Combined with functional studies employing pVIPR-specific cytotoxic T cells, our model study provides the basis to explain how citrullination can affect molecular interactions between MHC molecules and a peptide as well as T cell responses.
EXPERIMENTAL PROCEDURES
Cytotoxicity Assays-Peripheral blood cells were obtained from two B*2705-positive patients with AS. HLA-B27-restricted, pVIPR-specific cytotoxic T lymphocytes (CTLs) were generated and tested for specificity in a standard 4-h cytotoxicity assay as described previously (19) . Briefly, 51 Crlabeled T2-B*2705 or T2-B*2709 target cells were either incubated in medium alone (negative control) or in medium containing pVIPR or pVIPR-U5 (70 M, respectively). The effector/target ratio was 12:1 for the MP2 CTL and 15:1 for the CTL MP9 and MP11 as well as BO45. Spontaneous release of 51 Cr-labeled, washed target cells was lower than 15%. During the assay, the medium was devoid of peptide. The results summarize the data obtained from two independent experiments.
Monoclonal Antibodies and Peptide Binding Assays-The monoclonal antibodies ME1 (anti-HLA-B27, B7, B22, B73 HC⅐␤ 2 m complexes; IgG1 (22)), MARB3 (specific for HC⅐␤ 2 mpeptide complexes carrying the HLA-Bw4 determinant; IgM (23)), and appropriate negative isotype controls were employed to assess the binding of peptides to cell surface-expressed HLA-B27 subtypes (23) . For these tests, the transporter associated with antigen processing 2-negative cell line BM36.1 (24) transfected with B*2705 or B*2709 was employed. The cells were preincubated for 36 h at 26°C, the last 12 h in serum-free medium, and then incubated for 20 h at 26°C in the presence of peptide (50 M). The temperature was then elevated to 37°C for 4 h followed by a decrease to 4°C before incubation with appropriate monoclonal reagents and Alexa-labeled goat antimouse IgG. Single color analysis by flow cytometry was done on an EPICS-XL instrument (Coulter, Miami, FL) essentially as described (23) .
Expression, Purification, and Crystallization of the HLAB27⅐pVIPR-U5 Complexes-The high performance liquid chromatography-purified, citrulline-modified peptide (pVIPR-U5) was purchased from Alta Bioscience (Birmingham, UK). B*2705 and B*2709 HC and ␤ 2 m were expressed separately in Escherichia coli and purified from inclusion bodies following the protocol described previously (17) . Inclusion bodies of B*2705 HC or B*2709 HC and ␤ 2 m were then dissolved in 50% (w/v) urea and refolded for 2-3 weeks at 4°C in 400 mM L-arginine-HCl, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, and 100 mM Tris HCl, pH 7.5, in the presence of the peptide pVIPR-U5 (25) . A refolding period of at least 2 weeks has been found essential for efficient formation of heterotrimeric complexes with HLA-B27 HC (17) . The complexes were purified by size exclusion chromatography and concentrated in TBS buffer (20 mM Tris-HCl, 150 mM NaCl, 0.01% NaN 3 , pH 7.5) to 14.5 mg/ml (B*2705⅐pVIPR-U5) or 18 mg/ml (B*2709⅐pVIPR-U5). Crystals of HLA-B27⅐pVIPR-U5 complexes suitable for x-ray diffraction experiments were obtained using hanging drop vapor diffusion by mixing 1.8 l of precipitant solution (for B*2705⅐pVIPR-U5, 24% polyethylene glycol (PEG) 8000, 0.1 M Tris HCl, pH 7.5, and for B*2709⅐pVIPR-U5, 25% PEG 8000, 0.1 M Tris HCl, pH 8.0) and 1.8 l of protein solution and equilibrating the droplets with 750 l of precipitant solution. Streak seeding was used to improve crystal growth. For B*2705 and B*2709, the crystals obtained were square plates with a maximum size of 45 ϫ 45 ϫ 15 m.
Data Collection, Structure Determination, and RefinementCrystals of the complexes were cryo-protected by supplementing the precipitant solution with 30% polyethylene glycol 400 (B*2705⅐pVIPR-U5) and 20% glycerol (B*2709⅐pVIPR-U5). X-ray data were collected at 100 K on station ID29 at European Synchrotron Radiation Facility, Grenoble using a wavelength of 0.982 Å, processed with DENZO, and scaled with SCALEPACK (26) . The structures of B*2705⅐pVIPR-U5 and B*2709⅐ pVIPR-U5 were determined by molecular replacement using peptide-stripped B*2705⅐pVIPR (Protein Data Bank (PDB) code 1OGT) and B*2709⅐pVIPR (PDB code 1OF2) (19) as search models in program MOLREP (27) . Restrained maximum-likelihood refinement was performed using program REFMAC5 (28) . A topography file for the citrullinated peptide was generated using PRODRG server (29) , and the peptide was placed manually into the electron density using COOT (30) . Water molecules were included in the initial model with ARP/wARP (31). Further improvement of the structure was achieved by iterative cycles of manual rebuilding with COOT and maximum-likelihood refinement with REFMAC5. Structure validation was performed using programs WHATIF (32) and PRO-CHECK (33) . Angles were calculated with HBPLUS (34) and checked manually with COOT. Data collection and refinement statistics are given in Table 1 . The figures were generated using PYMOL (35) and LIGPLOT (36) . The atomic coordinates and structure amplitudes have been deposited in the Protein Data Bank under accession codes 3B6S (B*2705⅐pVIPR-U5) and 3B3I (B*2709⅐pVIPR-U5). The nomenclature used for the citrulline atoms in the PDB files was also employed under "Results" and "Discussion" and Table 2 . However, because this nomenclature makes a comparison with the corresponding atoms of arginine residues difficult, the correspondence between the two atom designations is given here (citrulline-arginine): O1-O, C1-C, C2-CA, N2-N, C3-CB, C4-CG, C5-CD, N6-NE, C7-CZ, O7-NH 2 , N8-NH1. (19) . Nevertheless, the unit cells are comparable because the axes a and b are isomorphous, whereas the axis c in space group P2 1 2 1 2 1 is almost twice as long as in P2 1 to accommodate four instead of two crystal asymmetric units. A close relation between molecular packing and C2 symmetries indicates that only marginal changes in crystal packing are required to transform from one space group into the other. Therefore, an in-depth comparison of the structures of B*2705 and B*2709 complexed either with the citrullinated or the unmodified pVIPR peptide is justifiable despite the presence of different space groups in which the complexes crystallized.
RESULTS

General
The structures of HC and ␤ 2 m of both subtypes in complex with pVIPR-U5 are nearly identical, with root mean square deviations (r.m.s.d.) of 0.6 Å. Asp-116 in B*2705 and His-116 in B*2709 are well defined in the respective electron densities, and this was also the case for the peptide (Fig. 1, A and B, and supplemental Fig. S1 ). However, pVIPR-U5 is bound in grossly different conformations by the two subtypes. It occurs in B*2705 in a canonical, conventional conformation previously termed "p4␣" (Ref. 19 ; main chain (Ϫ84.7°) and (Ϫ47.5°) torsion angles in an ␣-helical conformation at p4, and all other / torsion angles as in ␤-strands), with the partially solvent-exposed side chain of pCir5 pointing toward the ␣2-helix (Fig.  1C) . In contrast, pVIPR-U5 displays the non-canonical "p6␣" binding mode in the B*2709 subtype (main chain (Ϫ121.7°) and (27.0°) torsion angles in ␣-helical conformation at p6, and all other / torsion angles as in ␤-strands). As a consequence, the pCir5 side chain is embedded within the binding groove and forms a hydrogen bond with His-116 of the HC ( Fig. 1D ; Table  2 ). Therefore, the pVIPR-U5 conformation in B*2705 is similar to the canonical binding mode observed for pVIPR in both B*2705 and B*2709 (main chain torsion angles ϭ Ϫ85.2°, and ϭ Ϫ32.6°), whereas the B*2709⅐pVIPR-U5 structure resembles pVIPR bound to the B*2705 subtype in non-canonical conformation (main chain torsion angles ϭ Ϫ106.4°and ϭ 34.7°) (19) . The structures of the two subtypes with the citrullinated peptide diverge considerably from p3 to p7 (Fig. 1E ). However, a comparison of the B factors of the pVIPR-U5 peptide in the two subtypes shows that they are similar, with the exception of pCir5, which exhibits a much higher flexibility in B*2705 than in B*2709, where it is buried within the binding groove (Fig. 1, F and G). a Values in parentheses refer to the highest resolution shell. Despite the different peptide binding modes of pVIPR-U5 in B*2705 and B*2709, the primary anchor pArg2 as well as the secondary anchors pArg1 and pLeu9 are bound nearly identically in the two structures to the pockets B, A, and F, respectively, of the peptide binding groove (supplemental Fig. S1 ). Virtually identical orientations are also found in the case of the solvent-exposed side chain of pHis8 (supplemental Figs. S2 and S3; Fig. 1, C-E) . The firm anchoring of pArg2 within the B pocket (37) constitutes an highly conserved feature of all HLA-B27 structures solved so far (Refs. 38, 39; for review, see Ref. 14) , whereas the conformations of residues at p1, p8, and p9 resemble those found previously in case of the unmodified pVIPR bound to B*2705 or B*2709 (19) .
Conformation-dependent pVIPR-U5 Interactions in Complexes with
B*2705 and B*2709-As expected from the differential anchoring of the central portion of the two peptides, the C␣ backbones and the side chains of the intervening amino acids from p3 to p7 differ drastically in their orientations (Fig. 1E ). pArg1 and pHis8 as well as pTrp4 are fully solvent-accessible, and pCir5 and pArg6 as well as pTrp7 are partially solvent-accessible in B*2705 (Fig.  1C) . Furthermore, pCir5 and pArg6 are the most flexible peptide side chains, as indicated by elevated B values (Fig. 1F ). In the other subtype, however, pCir5 and pTrp7 are buried, and pTrp4 and pArg6 are fully solvent-exposed, whereas pLys3 is partly accessible (Fig. 1D) . The re-orientation of the peptide in B*2709 leads also to loss of pCir5 flexibility; only pArg6 retains increased B values (Fig. 1G) .
In B*2705 (supplemental Fig. S2 ; the peptide (Table 2) . Apart from further intrapeptide and intermolecular interactions involving residues in the middle of the peptide, the non-canonical conformation of pVIPR-U5 also leads to a characteristic stacking of the side chains of pTrp4 and pArg6 (Fig. 1B) which we have observed before in the case of the unmodified pVIPR peptide when bound to B*2705 in p6␣ conformation (19) .
The high resolution of the two structures also permitted the unambiguous identification of many water molecules that mediate further interactions both between peptide and HC residues as well as intrapeptide contacts (not shown). However, as found previously in the case of the m9 peptide (17), the polymorphic HC residue 116 is instrumental in the formation of distinct, subtype-specific water networks surrounding Asp/His-116. In particular, those regions within the binding groove are affected where the two peptide conformations differ most, i.e. between the D and the F pockets, as described already for the two pVIPR conformations (19) . Table 2 ). Small deviations are observed only in case of pCir5/pArg5 and pTrp7. However, the structures diverge considerably when B*2705 in complex with pVIPR-U5 and pVIPR in p6␣ binding mode are compared (r.m.s.d. of 3.6 Å for all, and 1.6 Å for the C␣ atoms of the peptides). In this case, the C␣ traces as well as the side chains of residues p3 to p7 are clearly distinct between the two structures (Fig. 2, B and E; supplemen- Table 2 ). In contrast, the structures of pVIPR in p6␣ conformation (B*2705) and pVIPR-U5 in B*2709 are virtually indistinguishable (r.m.s.d. of 0.8 Å for all, and 0.4 Å for C␣ atoms) (Fig. 2, D and E; supplemental Figs. S3 and S5; Table 2 ).
The similarity between B*2705⅐pVIPR-U5/B*2705⅐pVIPR-p4␣ and B*2709⅐pVIPR-U5/B*2705⅐pVIPR-p6␣ extends even to details of F pocket architecture (Fig. 3) . In the case of the two p4␣ binding modes, only the orientation of the pCir5/Arg-5 side chains differs appreciably, whereas all other peptide and HC residues retain their locations ( Figs. 2A and 3, A and B ; Table 2 ). Even more striking is the conserved architecture around pArg5 and pCir5 in the p6␣ peptide binding modes. Despite the presence of a bidentate salt bridge to Asp-116 in B*2705⅐pVIPR-p6␣ (Fig. 3C ) as opposed to a hydrogen bond to His-116 in B*2709⅐pVIPR-U5 (Fig. 3D ) and some altered intrapeptide contacts, the positions of all peptide and HC side chains are nearly perfectly retained (Fig. 3, C and D; supplemental Figs. S3 and S5; Table 2 ). The only slight difference concerns an "upward" movement of the pCir5 side chain (a difference of 1.8 Å between the corresponding pCir5 C7 and pArg5 CZ atoms) that is induced by the bulky His-116 side chain in B*2709 (Fig. 3, C and D) .
The two types of peptide conformation also influence the surface properties of the complexes (Fig. 4) . Due to the less exposed location of pCir5 in B*2705 in comparison to pArg5 in B*2705 (p4␣ binding mode) or B*2709 (Fig. 4, A and B) , the exposed peptide surface is smaller in the former complex: 146 Å 2 (B*2705⅐pVIPR-U5) in contrast to 160 Å 2 in both B*2705⅐pVIPR-p4␣ and B*2709⅐pVIPR, respectively. One consequence of the presence of the positively charged pArg5 in the latter structures is also a pronounced surface charge difference between B*2705⅐pVIPR-U5 and the two other complexes (Fig. 4, E and  F) . In contrast, the "disappearance" of the differently charged residues at peptide position p5 within the peptide binding groove leads to nearly complete congruence of the B*2705⅐pVIPR-p6␣ and the B*2709⅐pVIPR-U5 structures (Fig. 4, C and D) and identity in surface charge distribution (Fig.  4, G and H) .
Peptide-and Subtype-dependent CTL Recognition-The determination of the structures of the two HLA-B27 subtypes complexed with pVIPR-U5 suggested that pVIPR-specific CTL from a B*2705-positive donor might lose their reactivity when the citrullinated peptide would serve as target, assuming that it is presented also at physiological temperature in the conformation shown by the x-ray structures. We first determined whether pVIPR-U5 could be displayed by B*2705 and B*2709 at the cell surface using a binding assay that employed monoclonal antibodies. One of these (MARB3) is a conformationsensitive reagent recognizing HLA-B27 molecules only when a peptide is present within the binding groove (23) , whereas another (ME1) detects these molecules also in a peptide-devoid state (22) . The reactivity of both antibodies with the pVIPR-U5-loaded HLA-B27 subtypes indicates that citrulline-modified pVIPR forms complexes with these molecules that are stable at 37°C (Fig. 5, A and B) .
We had previously shown that pVIPR-specific CTL can be found in healthy B*2705-positive individuals and are frequently observed in patients with AS, whereas these CTL are only rarely encountered in B*2709-positive individuals (40, 41) . Such CTL could readily also be produced in the course of the current studies. As expected, they react with B*2705 and cross-react with the B*2709 subtype presenting the pVIPR peptide. How- Table 2 ) are depicted.
ever, none of the four CTL analyzed reacted with B*2705⅐pVIPR-U5, and there was only marginal reactivity with B*2709⅐pVIPR-U5 in case of one CTL (MP11) (Fig. 5C) .
DISCUSSION
Although the deimination of arginine to yield citrulline had been discovered as early as 1939 (42) , the importance of this posttranslational modification has only recently begun to be appreciated (1-6). To a large extent this is due to the finding that early diagnosis of a subset of patients with rheumatoid arthritis is facilitated by determining the presence of autoantibodies directed against cyclic citrullinated peptides (Refs. [43] [44] [45] [46] ; for a recent review, see Ref. 6) . T cell studies in combination with considerations based on the structure of MHC class II molecules in complex with unmodified peptides (1, 4) indicate that citrullinated peptides are displayed by these antigens but possibly in conformationally altered forms. Because evidence for an altered presentation of a citrullinated peptide had so far been obtained only indirectly, the present study addresses three issues that are important in the context of inflammatory disorders in general and HLA-B27-associated diseases in particular. (i) How can a citrullinated peptide be bound to and presented by an MHC molecule? (ii) Are the conformations exhibited by a citrullinated peptide and its nonmodified form different? And finally, (iii) do HLA-B27 subtypes that are differentially associated with AS display a given citrullinated peptide in a similar conformation? X-ray crystallography has been employed here for the first time to analyze the influence of a citrulline within a peptide on its presentation by MHC molecules. We chose to modify the pVIPR peptide because of the highly unusual dual binding mode which it exhibits when bound to the AS-associated B*2705 subtype. Furthermore, the central pArg5 occupies a strategic position (19) , making it likely that the exchange of pArg5 by pCir5 had an effect on peptide display, and above all, the frequent presence of cytotoxic T cells against this peptide only in B*2705 individuals suggests a relationship with the development of AS (19, 40 , for a review, see Ref. 41) . However, it is currently unclear whether vasoactive intestinal peptide type 1 receptor can be modified by citrullination such that pVIPR-U5 could be cleaved from it or whether the proteolysis-derived peptide might itself be subject to citrullination. In this context, it is important to point out that it is principally possible that pVIPR is just an innocent bystander in AS development as unidentified peptides that exhibit structural, but not necessarily sequence similarity with pVIPR might be the pathogenetically relevant targets that are recognized by cross-reactive CTL (20, 21) . Therefore, the model character of our study has to be emphasized.
Nevertheless, pVIPR-U5 can be bound by both B*2705 and B*2709 under in vitro (Fig. 1) as well as in vivo (Fig. 5) conditions, and the loss of the positive charge of pArg5 in pVIPR-U5 is accompanied by loss of the non-canonical (p6␣) conformation in B*2705. This is perhaps not surprising since citrullination of pArg5 had removed the positive charge which was considered a prerequisite for attaining this binding mode (19, 20) . However, the presence of the citrullinated peptide in a non-canonical conformation in B*2709 was unexpected. Therefore, this peptide is displayed in binding modes that are diametrically opposed to those exhibited by pVIPR ( Figs. 1-4 ; Table 2 ).
Why is pVIPR-U5 bound to B*2709 in the p6␣ conformation and to B*2705 in the p4␣ binding mode? In principle, the amide group of the pCir5 side chain could hydrogen bond to both His-116 and Asp-116 by an ϳ180°rotation. This would allow interactions either of pCir5 O7 with His116 NE2 (in fact found in B*2709) or of pCir5 N8 with Asp116 OD1 (not found in B*2705). There are two reasons why the latter scenario could be unfavorable (Fig. 3) . First, the distance of the Asp116 OD1 atom from the C␣-atom corresponds to that of His116 ND1 and not to that of His116 NE2 . It would be ϳ1.3 Å shorter and, therefore, possibly too short to be accommodated by conformational changes of the side chain of pCir5 or the C␣-backbone of the HC. Second, in B*2709⅐pVIPR-U5, pCir5 side chain atoms are engaged not only in a hydrogen bond to His116 NE2 but also to Lys70 NZ and Asp77 OD2 of the HC as well as to pTrp7 O of the peptide (Table  2 ). These contacts are both short and well defined because Lys70 NZ and Asp77 OD2 are charged, and there are water-mediated hydrogen bonds to the amide group as well (not shown). If the latter were rotated by ϳ180°in the B*2705 peptide binding groove, these hydrogen bonds would be replaced by repulsive interactions, because the oxygen of the amide group would now oppose Asp77 OD2 , and the amino group would be repelled by Lys70 NZ . In addition, it appears possible that a short intrapeptide contact (pCir5 N6 3 pTrp7 O ) would be lost as well, resulting in a further destabilization of pCir5-bound non-canonically to the B*2705 peptide binding groove.
The differential binding modes of pVIPR-U5 to the two HLA-B27 subtypes provide also an explanation for the loss of pVIPR-specific CTL reactivity with B*2705. Although the canonical binding mode of pVIPR-U5 is similar in structural terms to the conventional conformation observed for pVIPR (Figs. 2-4) , the electrostatic surface charges of the two complexes differ substantially in the vicinity of the pArg5/pCir5 exchange (Fig. 4) . This property is most likely responsible for the observation that none of the pVIPR-specific CTL exhibited cross-reactivity between the two peptides when displayed by the B*2705 subtype (Fig. 5) . Loss of the peptide from the binding groove during the cytotoxicity assay could be excluded because it was possible, using a conformation-sensitive monoclonal antibody, to demonstrate that pVIPR-U5 was stably bound to both subtypes (Fig. 5) . Furthermore, the lack of crossreactivity with B*2709⅐pVIPR-U5 in the case of the CTL MP2, MP9, and BO45 suggests that these three CTL recognize pVIPR in the canonical conformation because only this binding mode differs from the non-canonical presentation of pVIPR-U5 in B*2709 (Figs. 2 and 4) . In contrast, the marginal reactivity observed for MP11 in case of B*2709 (but not B*2705) complexed to pVIPR-U5 could indicate that some T cells within this CTL line recognize the non-canonical conformation of pVIPR in B*2705, as only this binding mode corresponds very closely to pVIPR-U5 bound non-canonically to B*2709.
The unpredictable effect even of seemingly minor changes within a peptide (47) (48) (49) (50) or an MHC class I HC (19, 20, 50, 51) on the interaction of an MHC-peptide complex with a TCR has recently been highlighted by extensive structural and dynamic analyses of HLA-A2 in complex with various related peptides derived from a melanoma-associated antigen (52) . This study demonstrated that neither cross-reactivity nor selectivity of T cells can reliably be predicted from x-ray structures of HLA-A2-peptide complexes, although the structural differences were much smaller than those reported here. Therefore, our finding that a single, strategically located polymorphic HC residue as well as a single charge difference within a peptide side chain (pArg5 versus pCir5) can independently affect the peptide binding mode is in line with the results reported for other MHC-peptide complexes.
It is currently unknown to what extent the citrullination of proteins, let alone that of the pVIPR peptide, influences T cell responses in diseases associated with distinct MHC alleles, as the only two reported cases involve the presentation of citrullinated peptides by selected mouse or human MHC class II antigens (1, 4) . Therefore, it would belong into the realm of speculation to ascribe a specific role to citrullinated peptides in the pathogenesis of autoimmune disorders; for example, in the context of molecular mimicry between foreign and self-peptides in AS (14, 20, 21) or other diseases. Whether conformational reorientations of MHC ligands, comparable with those described here, can affect also citrullinated pathogen-derived peptides such as pLMP2 (RRRWRRLTV; from the latent membrane protein 2 of Epstein-Barr virus) remains to be investigated. Like pVIPR, unmodified pLMP2 is presented by the B*2705 and B*2709 subtypes in completely different binding modes (20) , and it appears possible that citrullination of pLMP2 would affect its binding modes to HLA-B27 subtypes in ways analogous to those described here for the pVIPR peptide.
Citrullinated peptides have so far not been eluted from HLA-B27 antigens or other MHC molecules, although this may simply be because no attention had been paid to their possible presence. However, preliminary results have shown that HLA-B27-restricted CTL against pVIPR-U5 can be obtained from AS patients, 4 indicating that citrullinated pVIPR can indeed serve as a target in the context of physiological T cell responses. In line with these findings, citrullinated proteins are known to be expressed in synovial tissue of patients with a variety of autoimmune disorders including reactive arthritis, which is, like AS, an HLA-B27-associated disease (5) . Furthermore, citrullinemodified polypeptides have been found within the synovia of animals with collagen-and streptococcal cell wall-induced arthritis (53) . In addition, an analysis of synovial tissue from a patient with rheumatoid arthritis has demonstrated that 51 (5.2%) of 990 identified synovial proteins exhibited citrullination, and 13 citrullinated autoantigens could unambiguously be assigned by mass spectrometry (54) . Apart from fibrinogen, a major citrullinated autoantigen in these patients (55, 56) , all other proteins identified in this study (54) were polypeptides for which citrullination had not been described previously. Similarly, a comparative proteomic study (see Ref. 57 ) with a small number of patients exhibiting three types of rheumatoid disease indicates that citrullination is detectable not only in individuals with rheumatoid arthritis but also in those suffering from AS. There can, thus, be no doubt that a comparative proteomic approach with inflamed tissue from patients with AS and other spondyloarthropathies would lead to novel insights despite the fact that the clinical and pathogenetic parallels between these diseases and rheumatoid arthritis are limited.
In conclusion, the crystallographic and functional comparison of the two HLA-B27 subtypes in complex with pVIPR-U5 and pVIPR that we have carried out reveals three major findings. (i) Both subtypes are able to bind a given citrullinated peptide (pVIPR-U5), but they solve this task differently and present the peptide in drastically distinct conformations; (ii) the corresponding unmodified peptide (pVIPR) is displayed by a given HLA-B27 subtype in a diametrically opposing binding mode; (iii) the structural data provide an explanation for the results obtained with cytotoxic T cells but demonstrate also that citrullinated peptides may influence immune responses in an unpredictable manner.
